Methylglyoxal (MGO)

Methylglyoxal (MGO) is a highly reactive dicarbonyl compound (formula: C₃H₄O₂) that occurs as a byproduct of several metabolic pathways, particularly glycolysis, where it forms from nonenzymatic degradation of intermediates such as glyceraldehyde-3-phosphate and dihydroxyacetone phosphate[1][3][4][5]. It is also known as 2-oxopropanal and pyruvaldehyde[5]. Methylglyoxal is cytotoxic and reacts readily with proteins and nucleic acids, leading to the formation of advanced glycation end products (AGEs). This reactivity links MGO to a variety of pathological states, including diabetic complications, cancer, cardiovascular diseases, neurodegenerative disorders, and inflammation[1][3][4]. MGO is detoxified by the glyoxalase system (glyoxalase I and II using glutathione)[1]. It is not a therapeutic target such as an enzyme, receptor, or transporter; instead, it acts as a reactive intermediate and a biomarker of metabolic imbalance and oxidative stress, particularly in diabetes. Manuka honey contains high levels of methylglyoxal, contributing to its antibacterial activity, but no clinically approved drugs directly target MGO[3]. Safety concerns with MGO include its cytotoxicity, propensity to form AGEs, and potential to induce tissue damage[1][4].

Other names

2-oxopropanalpyruvaldehydepyruvic aldehyde1,2-propanedioneacetylformaldehydepropanedione2-ketopropionaldehydeα-ketopropionaldehyde2-oxo-propanal2-oxopropionaldehydeBPGPVLGlyoxalmethyl1-ketopropionaldehydepropionaldehyde2-oxo-methyl-glyoxal